[Treatment of mucositis pain: News and prospects].

Traitement des douleurs de mucite : actualités et perspectives.

Journal

Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 15 01 2019
revised: 15 03 2019
accepted: 22 03 2019
pubmed: 11 6 2019
medline: 19 9 2019
entrez: 11 6 2019
Statut: ppublish

Résumé

Mucositis, an acute inflammation of the digestive mucosa, is one of the main toxicities secondary to oncological treatments. Among its consequences, mucositis-related pain is an important complication due to its intensity and repercussion, especially on quality of life. Treatment of pain plays a central role in management of mucositis. It must be multimodal, combining local and general opioid or non-opioid treatments, adapted to pain intensity and based on international recommendations updated in 2014. A systemic analgesic treatment with morphine with a patient-controlled analgesia device is often necessary in severe mucositis. In case of insufficient analgesia, use of co-analgesics (paracetamol, ketamine, anticonvulsants, and antidepressants) can improve analgesic control and reduce morphine doses. Non-drug strategies (distraction, relaxation, hypnosis) and preventive measures must be a major concern. Among them, laser therapy using a low power athermal laser beam, is a promising therapeutic strategy whose effectiveness is based on its analgesic, anti-inflammatory, and healing properties. Despite many available studies, there is a limited number of clinically effective therapies. New therapeutic agents for the prevention and treatment of mucositis and its pain, based on the biological phenomena involved, must be further developed to improve the efficacy of analgesia.

Identifiants

pubmed: 31178070
pii: S0007-4551(19)30198-5
doi: 10.1016/j.bulcan.2019.03.022
pii:
doi:

Substances chimiques

Analgesics 0
Analgesics, Opioid 0
Anti-Inflammatory Agents 0
Morphine 76I7G6D29C

Types de publication

Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

776-783

Informations de copyright

Copyright © 2019 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Léa Guerrini-Rousseau (L)

Université Paris-Saclay, Gustave Roussy, département de cancérologie de l'enfant et de l'adolescent, 114, rue Edouard-Vaillant, 94805 Villejuif, France. Electronic address: lea.guerrini-rousseau@gustaveroussy.fr.

Perrine Marec-Berard (P)

Institut d'hématologie et d'oncologie pédiatrie, centre Léon-Bérard, département d'oncologie pédiatrique, 69008 Lyon, France. Electronic address: perrine.marec-berard@ihope.fr.

Stéphanie Bolle (S)

Université Paris-Saclay, Gustave Roussy, département de radiothérapie, 94805 Villejuif, France. Electronic address: stephanie.bolle@gustaveroussy.fr.

Sophie Laurent (S)

Université Paris-Saclay, Gustave Roussy, centre d'études et de traitement de la douleur, 94805 Villejuif, France. Electronic address: sophie.laurent@gustaveroussy.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH